Milestone Scientific (MLSS)
XASE:MLSS
MLSS Stock Chart & Stats
$0.29
$0.17(16.41%)
At close: 4:00 PM EST
$0.29
$0.17(16.41%)
Day’s Range― - ―
52-Week Range$0.22 - $1.11
Previous CloseN/A
Volume1.27M
Average Volume (3M)172.66K
Market Cap
$22.13M
Enterprise Value$22.04M
Total Cash (Recent Filing)$1.11M
Total Debt (Recent Filing)$1.02M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding80,453,120
10 Day Avg. Volume233,274
30 Day Avg. Volume172,658
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)7.97
Price to Sales (P/S)2.50
P/FCF Ratio-7.64
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue2.46
Enterprise Value/Gross Profit3.44
Enterprise Value/Ebitda-3.92
Forecast
1Y Price Target
$1.00Price Target Upside244.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.06
Revenue Forecast (FY)$9.91M
Bulls Say, Bears Say
Bulls Say
Dental Revenue GrowthSteady growth in the Dental business provides a reliable revenue base that supports reinvestment and enables expansion into the medical pain-management market with the CompuFlo System.
Leadership And Commercial CapabilityAppointment of a new CEO and a global head of sales and marketing strengthens commercial leadership, enhancing brand visibility and recurring customer engagement.
Medicare-focused Commercial StrategyConcentrating marketing on geographies served by Medicare Administrative Contractors that approved the product leverages management relationships to increase penetration in existing accounts and improve reimbursement-driven adoption.
Bears Say
Analyst Estimate RevisionsAnalyst downgrades to forward revenue estimates reflect reduced confidence in near-term commercialization and may weigh on investor sentiment.
Medical Sales TractionLimited sales traction in the Medical business indicates challenges converting approvals into steady clinical adoption, creating downside risk to growth plans.
Milestone Scientific News
MLSS FAQ
What was Milestone Scientific’s price range in the past 12 months?
Milestone Scientific lowest stock price was $0.22 and its highest was $1.11 in the past 12 months.
What is Milestone Scientific’s market cap?
Milestone Scientific’s market cap is $22.13M.
When is Milestone Scientific’s upcoming earnings report date?
Milestone Scientific’s upcoming earnings report date is May 14, 2026 which is in 32 days.
How were Milestone Scientific’s earnings last quarter?
Milestone Scientific released its earnings results on Mar 31, 2026. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of -$0.015 by -$0.005.
Is Milestone Scientific overvalued?
According to Wall Street analysts Milestone Scientific’s price is currently Undervalued.
Does Milestone Scientific pay dividends?
Milestone Scientific does not currently pay dividends.
What is Milestone Scientific’s EPS estimate?
Milestone Scientific’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Milestone Scientific have?
Milestone Scientific has 80,453,120 shares outstanding.
What happened to Milestone Scientific’s price movement after its last earnings report?
Milestone Scientific reported an EPS of -$0.02 in its last earnings report, missing expectations of -$0.015. Following the earnings report the stock price went up 3.472%.
Which hedge fund is a major shareholder of Milestone Scientific?
Currently, no hedge funds are holding shares in MLSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Milestone Scientific
Milestone Scientific Inc. designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. The company also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, it provides CompuFlo Epidural, a computer controlled anesthesia system for use in various medical applications. Further, the company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Livingston, New Jersey.
MLSS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted clear progress: restructuring and cost actions led to improved operating losses, modest revenue growth, renewed commercial focus (digital marketing, Ambassador program) and an actionable plan for CompuFlo reimbursement and market expansion. Management provided concrete 2026 guidance ($9.8M–$10.2M) and a target to reach cash flow breakeven by early 2027. However, significant risks remain — cash on hand is limited ($1.1M), the company remains loss-making (full-year net loss $5.7M), gross profit was flat year-over-year, and key upside depends on regulatory approvals, reimbursement expansion and successful conversion of early commercial programs. Overall, positives and improvements are tangible but balanced by near-term liquidity and execution risks.View all MLSS earnings summariesMLSS Stock 12 Month Forecast
Average Price Target
$1.00
▲(244.83% Upside)
Technical Analysis
Retractable Technologies
―
Precision Optics Corporation
―
Nephros
―
Femasys
―
NexGel Inc
―
Ownership Overview
11.31% Insiders
3.38% Mutual Funds
0.55% Other Institutional Investors
82.24% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---